Georgy Sagaradze

Title: Georgy Sagaradze: Innovator in Immunotherapy Assessment

Introduction

Georgy Sagaradze is a prominent inventor based in Moscow, Russia. He has made significant contributions to the field of immunotherapy, particularly in the assessment of tumor microenvironments. With a total of 2 patents, his work is paving the way for advancements in cancer treatment.

Latest Patents

Sagaradze's latest patents focus on tumor microenvironment-based methods for assessing CAR-T and other immunotherapies. These methods aim to determine whether a subject is likely to respond to adoptive cell therapies, such as chimeric antigen receptor (CAR) T-cell therapy. The process involves identifying a subject's tumor microenvironment (TME) type based on a molecular-functional expression signature. Additionally, it assesses the likelihood of response to CAR T-cell therapy based on the TME type. In some cases, the methods also determine the lymphoma microenvironment (LME) type for lymphoma subjects, such as those with Diffuse Large B Cell Lymphoma (DLBCL), and identify the subject's prognosis based on this determination.

Career Highlights

Georgy Sagaradze is currently associated with Bostongene Corporation, where he continues to innovate in the field of cancer research. His work is instrumental in enhancing the understanding of how tumor microenvironments affect treatment responses.

Collaborations

Sagaradze collaborates with notable colleagues, including Anna Gribkova and Grigorii Nos. Their combined expertise contributes to the advancement of research in immunotherapy.

Conclusion

Georgy Sagaradze's contributions to immunotherapy assessment are significant and impactful. His innovative methods are set to improve patient outcomes in cancer treatment.